v3.26.1
Fair Value Measurements - Schedule of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Derivative Liabilities Embedded Derivative | 2029 Notes | 2029 Embedded Derivative    
Liabilities Measured on Recurring Basis    
As of beginning balance $ 83,904 $ 51,819
Changes in fair value 9,350 (14,593)
As of ending balance 93,254 37,226
Derivative Liabilities Embedded Derivative | 2025 Notes | 2029 Embedded Derivative    
Liabilities Measured on Recurring Basis    
As of beginning balance   2,915
Changes in fair value   (2,041)
As of ending balance   874
ImThera Contingent Consideration Arrangements Liability    
Liabilities Measured on Recurring Basis    
As of beginning balance 92,075 84,218
Changes in fair value 10,655 922
As of ending balance 102,730 85,140
ImThera Contingent Consideration Arrangements Liability | Cost of Sales    
Liabilities Measured on Recurring Basis    
Changes in fair value 1,100  
ImThera Contingent Consideration Arrangements Liability | Research and Development Expense    
Liabilities Measured on Recurring Basis    
Changes in fair value 9,600  
Derivative Assets Capped Calls | 2029 Notes | 2029 Capped Calls    
Assets Measured on Recurring Basis    
As of beginning period 36,551 23,735
Changes in fair value 1,726 (6,545)
As of ending period 38,277 17,190
Derivative Assets Capped Calls | 2025 Notes | 2029 Capped Calls    
Assets Measured on Recurring Basis    
As of beginning period   2,624
Changes in fair value   (1,819)
As of ending period   $ 805
Investment in Convertible Notes Receivable    
Assets Measured on Recurring Basis    
As of beginning period 3,000  
Changes in fair value 0  
As of ending period $ 3,000